Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19550858 | 1.00 | APLNR (0.53) | APLNR | |
| SCHEMBL19551003 | 1.00 | APLNR (0.53) | APLNR | |
| SCHEMBL19573956 | 0.86 | APLNR (0.55) | APLNR | |
| SCHEMBL20177561 | 0.83 | APLNR (0.52) | APLNR | |
| SCHEMBL21389834 | 0.82 | APLNR (0.54) | APLNR | |
| SCHEMBL19550946 | 0.78 | APLNR (0.57) | APLNR | |
| SCHEMBL19551037 | 0.78 | APLNR (0.57) | APLNR | |
| SCHEMBL19550947 | 0.78 | APLNR (0.57) | APLNR | |
| SCHEMBL21389835 | 0.76 | APLNR (0.50) | APLNR | |
| SCHEMBL20177578 | 0.76 | APLNR (0.44) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452466-B1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3452466-B1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3452466-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017192485-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192485-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | APLNR 2/4885 |
| US-10150760-B2 | Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor | TBXA2R, APLNR, GPR27 | APLNR 2/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | APLNR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.